Cipla Ltd.

Financial

	Cipla	Sun Pharma Inds.	Mankind Pharma
Operational Metrics
API Sector
US DMF Filings	1704.0 .	498.0 .	n/a
Pharmaceutical Sector
Number of ANDA's Filed in USA	273.0 .	624.0 .	55.0 .
Number of ANDA's Approved By USFDA	193.0 .	529.0 .	32.0 .
Domestic Sales Growth - YoY	8.9 %	9.5 %	n/a
R&D as a % of Total Sales	6.1 %	6.8 %	2.15 %
Financials
5 yr Average ROE	11.43 %	8.59 %	23.48 %
5yr average Equity Multiplier	1.39	1.42	1.4
5yr Average Asset Turnover Ratio	0.76	0.53	1.02
5yr Avg Net Profit Margin	10.96 %	11.42 %	16.52 %
Price to Book	4.58	6.03	11.26
P/E	30.69	40.52	54.93
5yr Avg Cash Conversion Cycle	-3.69 Days	-72.43 Days	-45.92 Days
Inventory Days	59.85 Days	48.56 Days	60.23 Days
Days Receivable	44.13 Days	53.89 Days	19.33 Days
Days Payable	114.64 Days	168.32 Days	132.42 Days
5yr Average Interest Coverage Ratio	23.71	27.62	47.23
5yr Avg ROCE	15.24 %	14.84 %	31.06 %
5yr Avg Operating Profit Margin	22.51 %	26.71 %	25.32 %
5 yr average Debt to Equity	0.13	0.13	0.07
5yr CAGR Net Profit	12.9 %	26.03 %	17.25 %
5yr Average Return on Assets	8.36 %	6.08 %	16.73 %
Shareholdings
Promoter Holding	33.47 %	54.48 %	74.88 %
Share Pledged by Promoters	0.0	2.05 %	0.0
Change in Promoter Holding (3 Yrs)	-3.26 %	0.0	-1.62 %
Change in Mutual Fund Holding (3 Yrs)	2.19 %	0.28 %	6.74 %

Business

	Cipla	Sun Pharma Inds.	Mankind Pharma
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 95.78 New ventures 4.22 API & Others 0 Western Europe & Other Markets 0 Emerging Markets 0 India Branded Formulations 0 US Formulations 0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0	Product Wise Break-Up New ventures 0 Pharmaceutical 0 Gynaecology 0 Cardiovascular 0 Active Pharmaceutical Ingredient (API) 6.0 Neuro/CNS 0 Anti-Diabetic 0 Pain/Analgesics 0 India Branded Formulations 31.0 Respiratory 0 VMN 0 Anti-infectives 0 Gastro - Intestinal 0 Dermatology 0 Western Europe & Other Markets 15.0 US Formulations 30.0 Emerging Market 18.0 Urology 0	Product Wise Break-Up New ventures 0 Pharmaceutical 0 Gynaecology 7.0 Cardiovascular 14.0 API & Others 0 Neuro/CNS 3.0 Anti-Diabetic 8.0 Pain/Analgesics 5.0 India Branded Formulations 0 Respiratory 9.0 VMN 10.0 Anti-infectives 17.0 Gastrointestinal 10.0 Dermatology 6.0 Western Europe & Other Markets 0 US Formulations 0 Emerging Markets 0 Urology 5.0 Others 6.0
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Respiratory Systems 38.9 Anti-Infective 15.3 Cardiac Science 11.7 Gastro Intestinal 5.8 Urology 4.8 Anti - Diabetes 3.8 Pain Management 3.5 Antivirals 3.1 Ophthalmology 3.1 Derma 2.7 Central Nervous System (CNS) 2.3 Gynaec. 0 Vitamins 0 Antineoplast 0 Oncology 0 Gastroenterology 0 Neuro-Psychiatry 0 Cardiology 0 Opthalmology 0 Gynaecology 0 Vitamins,Minerals & Nutrients 0 Dermatology 0 Diabetology 0 Anti-Infectives 0 Others 5.0	Therapeutic Area Wise Break-Up - Domestic Anti-Infective 9.0 Anti - Diabetes 9.0 Cardiac Science 0 Oncology 0 Dermatology 6.0 Antineoplast 0 Ophthalmology 3.0 Central Nervous System (CNS) 0 Central Nervous System (CNS) 17.0 Antivirals 0 Anti - Diabetes 0 Vitamins / Minerals / Nutrients 5.0 Anti-Infective 0 Pain Management 0 Gynecology 3.0 Gastro Intestinal 12.0 Urology 3.0 Derma 0 Respiratory Systems 0 Gastro Intestinal 0 Ophthalmology 0 Gynaec. 0 Cardiac Science 18.0 Vitamins 0 Others 15.0	-
Location Wise Break-Up	Location Wise Break-Up India 44.0 North America 29.0 SAGA 12.0 Rest of the World 11.0 Global API 2.0 Europe 0 Emerging Markets 0 USA 0 Nepal 0 Sri Lanka 0 Bangladesh 0 Others 2.0	Location Wise Break-Up USA 32.28 Europe 0 SAGA 0 Sri Lanka 0 Nepal 0 Bangladesh 0 India 32.72 Rest of the World 15.21 North America 0 Emerging Market 19.79 Global API 0	Location Wise Break-Up USA 0 Europe 0 SAGA 0 Sri Lanka 0 Nepal 0 Bangladesh 0 India 92.0 Rest of the World 0 North America 0 Emerging Markets 0 Global API 0 Others 8.0
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 100.0 New Ventures 0	-	-
Asset Break-Up	Asset Break-Up India 47.79 USA 30.05 South Africa 16.85 Others 5.31	-	-

Cipla Ltd.

SIGN UP FOR FREE